Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 26,000 shares, a drop of 72.3% from the September 30th total of 93,900 shares. Based on an average daily volume of 72,900 shares, the short-interest ratio is presently 0.4 days. Currently, 3.5% of the shares of the company are short sold.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Evoke Pharma in a report on Saturday, October 19th. They issued a “sell” rating for the company.
Read Our Latest Stock Analysis on Evoke Pharma
Evoke Pharma Stock Performance
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). The business had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Conference Calls and Individual Investors
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to invest in marijuana stocks in 7 steps
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.